tiprankstipranks
BIOTON S.A. (DE:7U5)
:7U5
Holding DE:7U5?
Track your performance easily

BIOTON S.A. (7U5) Stock Price & Analysis

0 Followers

7U5 Stock Chart & Stats


Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.23%99.77%
Insiders
― Other Institutional Investors
99.77% Public Companies and
Individual Investors

7U5 FAQ

What was BIOTON S.A.’s price range in the past 12 months?
BIOTON S.A. lowest stock price was €0.64 and its highest was €0.85 in the past 12 months.
    What is BIOTON S.A.’s market cap?
    BIOTON S.A.’s market cap is €70.01M.
      When is BIOTON S.A.’s upcoming earnings report date?
      BIOTON S.A.’s upcoming earnings report date is Mar 28, 2025 which is in 68 days.
        How were BIOTON S.A.’s earnings last quarter?
        BIOTON S.A. released its earnings results on Nov 08, 2024. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.009.
          Is BIOTON S.A. overvalued?
          According to Wall Street analysts BIOTON S.A.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does BIOTON S.A. pay dividends?
            BIOTON S.A. does not currently pay dividends.
            What is BIOTON S.A.’s EPS estimate?
            BIOTON S.A.’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does BIOTON S.A. have?
            BIOTON S.A. has 85,864,200 shares outstanding.
              What happened to BIOTON S.A.’s price movement after its last earnings report?
              BIOTON S.A. reported an EPS of -€0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.333%.
                Which hedge fund is a major shareholder of BIOTON S.A.?
                Currently, no hedge funds are holding shares in DE:7U5
                ---

                Company Description

                BIOTON S.A.

                Bioton SA is a Poland based company engaged in the principal business activity of manufacturing medicines and pharmaceutical preparations and production of pharmaceutical substances. The products of the company include recombinant human insulin in pharmaceutical substance form and as preparations for injections; glimepiride, an oral hypoglycemic drug; and metformin, an oral hypoglycemic drug. Its products line focuses on diet supplements, products for particular nutritional uses and cosmetics dedicated to patients with certain health problems. The group operates in Poland and internationally, of which majority of the revenue is derived from Poland.
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                FinLab AG
                Popular Stocks
                ---
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis